Compare Hims and Hers Health Inc (HIMS) vs Lufax Holding Ltd (LU) Price & Performance

HIMS stock trades at $28.06, down 5.01% on the day, amid a bearish technical signal and negative earnings surprises. The company reported a net loss of $142 million in 2026, with a negative net income margin of -5.51%, despite revenue growth to $2.6 billion. Multiple securities class action lawsuits filed in October 2026 create significant legal overhang, while analyst consensus remains mixed with a $32.17 price target but only 35% buy ratings.

The outlook is clouded by profitability challenges and legal risks, though revenue growth offers a potential catalyst if margins improve. Investors face substantial downside risk from ongoing litigation and weak earnings, offset by analyst price targets suggesting modest upside from current levels if operational execution improves.

LU trades at $0.98, down 0.11% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported a net loss of $2.10 billion on $23.11 billion revenue in 2025, with negative profit margins and ROE. Recent corporate actions include a 10:1 reverse stock split effective October 23, 2026. Analyst consensus remains positive with 69% buy ratings, though earnings have consistently missed expectations.

LU presents a deep value opportunity with P/S of 0.25 and P/B of 0.07, but faces significant execution risks amid declining revenue and persistent losses. The company's strong parent backing from Ping An and improving operational cash flow provide some stability, but regulatory headwinds in China's consumer lending market remain a concern for sustained recovery.